NYSE · DHR
Danaher Corporation
$236.94+$2.87 (+1.23%)
Danaher Corporation’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
Loading market information…
PAR · DIM.PA · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sartorius Stedim Biotech S.A.’s forward annual dividend is €0.69 per share, paid annual. The forward yield is 0.3% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Sartorius Stedim Biotech S.A.’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of €1.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sartorius Stedim Biotech S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Jul 22, 2025 | €1.22+17.31% vs estimate | €745.00M+1.06% vs estimate |
|---|
| Q1 2025 | Apr 16, 2025 | €1.09+23.16% vs estimate | €744.60M+11.37% vs estimate |
|---|
| Q4 2024 | Jan 28, 2025 | €1.04+8.67% vs estimate | €751.30M+3.16% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$236.94+$2.87 (+1.23%)
Danaher Corporation’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
₩1,423,000+₩57,000 (+4.17%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.38% below the high.
$416.67+$13.03 (+3.23%)
West Pharmaceutical Services, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.93% below the high.
HK$45.10+HK$0.04 (+0.09%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.24% below the high.
€298.50+€6.00 (+2.05%)
Sartorius AG’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
$188.64+$3.95 (+2.14%)
Repligen Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.14% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$16.68-$0.01 (-0.06%)
Avantor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.41% below the high.
